Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chineo Medical Technology Co. Ltd. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners, ensuring that no single examiner is responsible for the company's entire current workload. Furthermore, the portfolio is spread across 2 distinct art units, reflecting a range of technical classifications within their biotechnology filings.
XIAO, YAN serves as the busiest examiner for the portfolio, holding 1 pending action. This figure matches the workload of the other examiner, as the 2 pending actions are split evenly between the 2 distinct examiners. The presence of 2 distinct art units suggests that the company's intellectual property strategy involves different biological or pharmaceutical sub-categories, requiring the legal team to adapt to the specific standards of 2 different administrative groups. This distribution means that the outcome of the 2 pending actions will depend on the unique perspectives of 2 different examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIAO, YAN | 1 | 67.3% | +52.7% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033483 | MODIFIED IMMUNE CELL AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18518539 | MODIFIED IMMUNE CELLS AND USES THEREOF | XIAO, YAN | — |
| 18033483 | MODIFIED IMMUNE CELL AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18518539 | MODIFIED IMMUNE CELLS AND USES THEREOF | XIAO, YAN | 1642 | §102DP | Non-Final OA | — | Pending | Nov 23, 2023 |
| 18033483 | MODIFIED IMMUNE CELL AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§103 | Final Rejection | — | Pending | Oct 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial